Rifampin decreases the plasma concentrations and effects of repaglinide.
about
Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactamsModeling of rifampicin-induced CYP3A4 activation dynamics for the prediction of clinical drug-drug interactions from in vitro dataTuberculosis and diabetes mellitus: convergence of two epidemics.Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.Impact of OATP transporters on pharmacokinetics.New onset diabetes after transplantation (NODAT): an overview.Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects.Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide.Effect of rifampicin on the pharmacokinetics of pioglitazoneThe impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide.Serum- and glucocorticoid-regulated kinase 2 determines drug-activated pregnane X receptor to induce gluconeogenesis in human liver cellsRepaglinide: a review of its use in type 2 diabetes mellitus.Methods for the quantitative evaluation and prediction of CYP enzyme induction using human in vitro systems.Induction of cytochrome P450 enzymes: a view on human in vivo findings.A review of the efficacy and safety of oral antidiabetic drugsPredicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach.PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8.Transporter-mediated drug-drug interactions with oral antidiabetic drugs.Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide.CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide.Pregnane X receptor agonists impair postprandial glucose tolerance.The effect of acute administration of rifampicin and imatinib on the enterohepatic transport of rosuvastatin in vivo.Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers.Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide.Increased systemic exposure of fimasartan, an angiotensin II receptor antagonist, by ketoconazole and rifampicin.Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.Prediction of drug-drug interactions using physiologically-based pharmacokinetic models of CYP450 modulators included in Simcyp software.Dual effects of rifampin on the pharmacokinetics of atrasentan.The pregnane X receptor agonist St John's Wort has no effects on the pharmacokinetics and pharmacodynamics of repaglinide.Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers.
P2860
Q24631021-0B95A523-B099-4A9B-B03A-0390CECFFA95Q28533793-8D342ECD-32D3-40FF-BFB8-7D023A5520E9Q34156234-76E3F97C-5D3C-44BD-9F3A-96585CCA2DA9Q34561039-175B10EA-BF4C-4350-9AD9-D176905B745CQ34612244-A48A488D-6433-4315-B5F0-08F6880EF642Q35092351-5E9D5D1A-7E42-45BE-A391-E1BCA1D22049Q35825729-85540AF5-DD3A-4773-99B2-AC89B7369C5BQ35827146-A2B6EBA5-26FD-44ED-9F93-22F0DCEDA521Q35827325-AE70596D-C3E5-48B3-B816-D5FA796F1D7DQ35827353-B18428E2-76DB-4A11-8FA1-BB042B9DE3B5Q37405355-5E12915E-0486-41A4-A8D9-3FF1D11FE10CQ37977979-DB65ADB9-C844-4E89-9B89-1E836F78B1EBQ38028549-630EE26C-E213-4159-A344-CAF58AE1E1E6Q38057372-EA638815-BDA4-4E54-87AB-6715DCA804C0Q38067491-07BAEEBB-09AF-4788-BBE2-28034B9804D9Q38087695-ED730050-3321-485A-9154-DE3802812169Q38130410-F905679E-531E-4C16-BF38-10E29FB3CB9AQ38168993-72A95B1F-FF2A-478C-BD04-17B116063354Q38684505-C774F118-F018-40BE-9854-15A1049786B4Q39212609-18535694-E12C-4995-B245-C739DD2EDEF1Q41826580-356921FD-6B1B-4C37-837A-8896FA21AEF4Q42595219-D2A71BD5-DCB2-4F8A-B274-C5892DD60021Q43003337-A8A738A4-D011-44B9-9081-668256D601D6Q43235333-5E02F924-61C4-4210-AB9A-F4DF7C1FD725Q44484818-6B47B3CB-72C6-4B7A-8636-9DD72E6FD48FQ46132298-793497E9-C6B4-40B4-B191-B5DBAE55D023Q46813708-52DF6FD8-E52D-4141-B6B1-342FA9FDF221Q47924035-DC5F864C-5E65-4984-9EF9-9DD94173F179Q48473609-A968A06A-CF63-4ABA-93CF-6F482F46D0D0Q48809049-34CB7782-CF21-48E4-A19F-C06E5D8071C5Q54387375-497ACC8E-1949-4775-8875-FC748B8E531B
P2860
Rifampin decreases the plasma concentrations and effects of repaglinide.
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Rifampin decreases the plasma concentrations and effects of repaglinide.
@ast
Rifampin decreases the plasma concentrations and effects of repaglinide.
@en
Rifampin decreases the plasma concentrations and effects of repaglinide.
@nl
type
label
Rifampin decreases the plasma concentrations and effects of repaglinide.
@ast
Rifampin decreases the plasma concentrations and effects of repaglinide.
@en
Rifampin decreases the plasma concentrations and effects of repaglinide.
@nl
prefLabel
Rifampin decreases the plasma concentrations and effects of repaglinide.
@ast
Rifampin decreases the plasma concentrations and effects of repaglinide.
@en
Rifampin decreases the plasma concentrations and effects of repaglinide.
@nl
P2093
P356
P1476
Rifampin decreases the plasma concentrations and effects of repaglinide.
@en
P2093
P304
P356
10.1067/MCP.2000.111183
P407
P577
2000-11-01T00:00:00Z